These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36745212)

  • 1. Denosumab prevented periprosthetic bone resorption better than risedronate after total hip arthroplasty.
    Nakura N; Hirakawa K; Takayanagi S; Mihara M
    J Bone Miner Metab; 2023 Mar; 41(2):239-247. PubMed ID: 36745212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial.
    Sköldenberg OG; Salemyr MO; Bodén HS; Ahl TE; Adolphson PY
    J Bone Joint Surg Am; 2011 Oct; 93(20):1857-64. PubMed ID: 22012522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty.
    Yamasaki S; Masuhara K; Yamaguchi K; Nakai T; Fuji T; Seino Y
    Osteoporos Int; 2007 Jul; 18(7):1009-15. PubMed ID: 17554581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficiency of risedronate in reducing bone resorption after total hip arthroplasty: a meta-analysis of randomized control trials at a minimum of 6 months' follow-up.
    Yang L
    J Orthop Surg Res; 2018 Apr; 13(1):88. PubMed ID: 29665839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No effect of risedronate on femoral periprosthetic bone loss following total hip arthroplasty. A 4-year follow-up of 61 patients in a double-blind, randomized placebo-controlled trial.
    Muren O; Akbarian E; Salemyr M; Bodén H; Eisler T; Stark A; Sköldenberg O
    Acta Orthop; 2015; 86(5):569-74. PubMed ID: 25885280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventing Loss of Femoral Periprosthetic Bone Mineral Density in Cementless Total Hip Arthroplasty Using a Tapered Wedge Stem: A Retrospective, Cohort Study in Osteoporotic Patients Treated with Denosumab.
    Kamo K; Kijima H; Okuyama K; Kawano T; Seki N; Sato C; Kido T; Miyakoshi N
    Cureus; 2024 May; 16(5):e59908. PubMed ID: 38721477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of proximal periprosthetic bone loss by denosumab in cementless total hip arthroplasty.
    Nagoya S; Tateda K; Okazaki S; Kosukegawa I; Shimizu J; Yamashita T
    Eur J Orthop Surg Traumatol; 2018 Dec; 28(8):1601-1607. PubMed ID: 29774416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of denosumab on bone mineral density around proximal femoral prosthesis after total hip replacement in postmenopausal osteoporotic patients].
    Ning WH; Xu GZ; Wang JW
    Zhongguo Gu Shang; 2023 Nov; 36(11):1041-5. PubMed ID: 38012872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
    Brown JP; Roux C; Ho PR; Bolognese MA; Hall J; Bone HG; Bonnick S; van den Bergh JP; Ferreira I; Dakin P; Wagman RB; Recknor C
    Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial.
    Huang TW; Wang CJ; Shih HN; Chang Y; Huang KC; Peng KT; Lee MS
    BMC Musculoskelet Disord; 2017 May; 18(1):209. PubMed ID: 28532408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty: A systematic review and meta-analysis.
    Wang M; Wang L; Ye R
    Int J Surg; 2018 Apr; 52():189-200. PubMed ID: 29448032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of risedronate in improving bone mineral density in patients undergoing total hip arthroplasty: A meta-analysis of randomized controlled trials.
    Su J; Wei Y; Li XM; Diao YP; Liu HG; Zhang L
    Medicine (Baltimore); 2018 Dec; 97(51):e13346. PubMed ID: 30572438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis.
    Li Q; Xu B
    J Orthop Surg Res; 2018 Jun; 13(1):144. PubMed ID: 29880021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
    Saag KG; Pannacciulli N; Geusens P; Adachi JD; Messina OD; Morales-Torres J; Emkey R; Butler PW; Yin X; Lems WF
    Arthritis Rheumatol; 2019 Jul; 71(7):1174-1184. PubMed ID: 30816640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raloxifene Prevents Early Periprosthetic Bone Loss for Postmenopausal Women after Uncemented Total Hip Arthroplasty: A Randomized Placebo-Controlled Clinical Trial.
    Gong L; Zhang YY; Yang N; Qian HJ; Zhang LK; Tan MS
    Orthop Surg; 2020 Aug; 12(4):1074-1083. PubMed ID: 32686337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
    Välimäki MJ; Farrerons-Minguella J; Halse J; Kröger H; Maroni M; Mulder H; Muñoz-Torres M; Sääf M; Snorre Øfjord E
    Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficiency of Zoledronic Acid in Inhibiting Accelerated Periprosthetic Bone Loss After Cementless Total Hip Arthroplasty in Osteoporotic Patients: A Prospective, Cohort Study.
    Fu GT; Lin LJ; Sheng PY; Li CC; Zhang JX; Shen J; Liu S; Xue YL; Lin SP; Wang K; Zheng QJ; Ding Y
    Orthop Surg; 2019 Aug; 11(4):653-663. PubMed ID: 31456320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab Prevents Early Periprosthetic Bone Loss After Uncemented Total Hip Arthroplasty: Results from a Randomized Placebo-Controlled Clinical Trial.
    Nyström A; Kiritopoulos D; Ullmark G; Sörensen J; Petrén-Mallmin M; Milbrink J; Hailer NP; Mallmin H
    J Bone Miner Res; 2020 Feb; 35(2):239-247. PubMed ID: 31589776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-osteoporotic drug efficacy for periprosthetic bone loss after total hip arthroplasty: A systematic review and network meta-analysis.
    Hatano M; Koizumi Y; Yamamoto N; Miyoshi K; Kawabata K; Tanaka T; Tanaka S; Shiroshita A; Kataoka Y
    J Orthop Sci; 2024 Feb; ():. PubMed ID: 38342711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.